Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	5.93M 18.07M 5.21M 4.85M 4.45M 8.35M 571M 8.48M 57.53M 22.48M 281M 22.27M 21.79M 971M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.93M 18.07M 5.21M 4.85M 4.45M 8.35M 571M 8.48M 57.53M 22.48M 281M 22.27M 21.79M 971M	EV / Sales 2026 *	4x	EV / Sales 2027 *	2.28x
Free-Float	82.98%	Yield 2026 *	-	Yield 2027 *	-

07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
05-18	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-02	Evogene reports receipt of Nasdaq minimum bid price notification	RE
04-02	Evogene Gets Nasdaq Minimum Bid Price Notification	MT

23-10-02	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
23-08-18	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
21-07-29	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
20-12-01	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

07-22	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
07-08	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
05-20	Evogene : Q1 2026 Consolidated Financial Statements	PU
05-20	Evogene: Q1 Earnings Snapshot	AQ

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	2004-11-30
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	2021-12-31

Evogene Ltd. Stock TEL AVIV STOCK EXCHANGE

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd.

Latest news : Evogene Ltd.

Last Transcript: Evogene Ltd.

Analysts' recommendations: Evogene Ltd.

Press Releases: Evogene Ltd.

News in other languages: Evogene Ltd.

Quotes and Performance

Managers and Directors: Evogene Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Dan Falk BRD	Director/Board Member	81	2021-11-16
Sarit Firon CHM	Chairman	60	2021-05-31
Leon Recanati BRD	Director/Board Member	77	2010-06-02

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	-1.98%	-7.28%	-	-	5.93M
LONZA GROUP AG	+1.07%	-3.49%	-3.25%	+12.87%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+408.41%	+629.49%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+9.93%	+66.92%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+3.60%	-8.81%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+3.37%	+38.15%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+31.97%	+143.53%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	+0.76%	+8.50%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-15.00%	-31.68%	12.7B
Average	+0.00%	+0.83%	+54.97%	+107.37%	27.25B
Weighted average by Cap.	+0.48%	+0.91%	+75.32%	+136.64%

	2026 *	2027 *
Net sales	1.48M 4.52M 1.3M 1.21M 1.11M 2.09M 143M 2.12M 14.39M 5.62M 70.26M 5.57M 5.45M 243M	2.6M 7.92M 2.28M 2.12M 1.95M 3.66M 250M 3.72M 25.22M 9.85M 123M 9.76M 9.55M 426M
Net income	-16.69M -50.82M -14.66M -13.63M -12.51M -23.5M -1.61B -23.86M -162M -63.23M -790M -62.64M -61.29M -2.73B	-13.92M -42.38M -12.22M -11.37M -10.43M -19.6M -1.34B -19.9M -135M -52.73M -659M -52.24M -51.11M -2.28B
Net Debt	-	-